Advertisements

Stocking Stuffers

 

Acerus Pharmaceuticals Corporation (ASP:CA) Stock Quote

Detailed Quote for Acerus Pharmaceuticals Corporation (ASP:CA)
$ 0.175   0.005 (+2.94%) Volume: 435.52k 3:49 PM EDT Mar 22, 2019
Today 5d 1m 3m 1y more
Last Price
0.175
Change $
0.005
Change %
2.94%
Tick
  
Bid
0.165
Bid Size
18,000
Ask
0.18
Ask Size
20,000
Open
0.175
High
0.195
Low
0.16
Prev Close
0.17
Last Trade
03/22/19
Volume
435.52k
52 Wk Hi
0.400000005
52 Wk Low
0.104999996
Market Cap
41.19m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
235,384,262
EPS (TTM)
-0.109999999
PE Ratio
N/A
Exchange
TSX
News and Media for Acerus Pharmaceuticals Corporation (ASP:CA)
Sector News | Topic News
News for Acerus Pharmaceuticals Corporation (ASP:CA)
Tue, Mar 05, 2019
7:00 AM Acerus Reports Fourth Quarter and Full Year 2018 Financial Results - Business Wire
7:00 AM Acerus Reports Fourth Quarter and Full Year 2018 Financial Results - Business Wire Canada
Mon, Mar 04, 2019
7:00 AM Acerus Files a New Drug Submission for Avanafil in Canada - Business Wire
7:00 AM Acerus Files a New Drug Submission for Avanafil in Canada - Business Wire Canada
Wed, Feb 27, 2019
7:00 AM Acerus Provides Business Update on NATESTO\u00AE - Business Wire Canada
7:00 AM Acerus Provides Business Update on NATESTO\u00AE - Business Wire
Tue, Feb 26, 2019
7:00 AM Acerus to Report 2018 Financial Results and Host Investor Call - Business Wire
7:00 AM Acerus to Report 2018 Financial Results and Host Investor Call - Business Wire Canada
Fri, Jan 25, 2019
7:00 AM Acerus Receives Notice of Deficiency - Withdrawal Letter from Health Canada Regarding Gynoflor(TM) Application - Business Wire
Mon, Jan 14, 2019
8:00 AM Today's Research Reports on Helius Medical Technologies, Titan Medical, IMV and Acerus Pharmaceuticals - ACCESSWIRE IA
Fri, Jan 11, 2019
6:00 PM Acerus Announces Reporting of Anticipated Shortage of ESTRACE\u00AE - Business Wire
Tue, Dec 11, 2018
7:00 AM Acerus Announces Results of Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil - Business Wire
Wed, Dec 05, 2018
7:45 AM Today's Research Reports on Acerus Pharmaceuticals, GeneNews, Resverlogix and Hamilton Thorne - ACCESSWIRE IA
Mon, Nov 26, 2018
7:00 AM Acerus Provides Update on Continuing Commercial and R&D Achievements for NATESTO\u00AE - Business Wire
Tue, Nov 06, 2018
7:00 AM Acerus Reports Third Quarter 2018 Financial Results - Business Wire
Wed, Oct 31, 2018
8:00 AM Today's Research Reports on Trillium Therapeutics, Cipher Pharmaceuticals, Acerus Pharmaceuticals and Helius Medical Technologies - ACCESSWIRE IA
7:00 AM Acerus Announces Expansion of NATESTO\u00AE Agreement with medac and the Submission of NATESTO\u00AE Dossier in Europe - Business Wire
Tue, Oct 30, 2018
5:00 PM Acerus to Report Third Quarter 2018 Financial Results and Host Investor Call - Business Wire
8:00 AM Acerus Announces Executive Leadership Changes in Corporate Finance - Business Wire
Wed, Oct 24, 2018
5:00 PM Acerus Announces Initiation of a Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil - Business Wire
More News for ASP:CA >>

Tags for Acerus Pharmaceuticals Corporation

Research stocks or mutual funds related to Acerus Pharmaceuticals Corporation by keywords or tags. Find companies that have a similar focus to ASP:CA. The keywords below have been associated to ASP:CA by either user submission or electronic means.

Common Stock Industrial Goods Aerospace Product and Parts Manufacturing (336410) Aircraft and Aircraft Parts Industry (3211) Aerospace/Defense